Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Real Time & Level II Data
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Spero Therapeutics Inc
SPRO
Healthcare
Biotechnology
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant (MDR) bacterial infections, and rare diseases where there is unmet medical and patient need. Its lead product candidate, tebipenem pivoxil hydrobromide (tebipenem HBr) is designed...
to be the oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections (cUTIs), including pyelonephritis, caused by certain microorganisms, in adult patients who have limited oral treatment options. Its pipeline also includes SPR720 and SPR206. SPR720 is designed to be the oral treatment for non-tuberculous mycobacterial (NTM) infection. SPR206 is a direct acting intravenous (IV)-administered polymyxin analogue developed from its potentiator platform to treat MDR Gram-negative bacterial infections in the hospital setting.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:SPRO)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 19, 2022 8:05am
New Press Release - Spero Therapeutics to Present Data at IDWeek 2022
CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 03, 2022 8:05am
New Press Release - Spero Therapeutics to Host Virtual R&D Event on Non-Tuberculous Mycobacterial Pulmonary Disease and the SPR720 Program
Event is taking place on Thursday, October 6th at 11:30 a.m. ET Event will feature a presentation by key opinion leader, Kevin L. Winthrop, MD, MPH (Division of Infectious Disease, OHSU Medical School)CAMBRIDGE, Mass., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO...
read article.
Oil & Gas Co. Surpasses Expectations: Spearheading Success in the Oxbow Area and More for 2023
posted Sep 21, 2023 9:00am by
Saturn Oil & Gas Inc.
-
|
"Our Spearfish light oil drilling program has generated capital efficiencies that are among the strongest we've seen across our asset base, and have outperformed our internal expectations, which confirms the extensive multizone development opportunities offered by our Oxbow asset ...read more
(81)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 22, 2022 1:10pm
SPRO ....can'y win em all
Sorry
(81)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 22, 2022 1:08pm
SPRO ..... watching for Volume increase and Price Action
Might run again....currently at ~$2.40
(81)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 22, 2022 12:41pm
SPRO .... In PB mode
Stops save portfolios....just sayin ; ) Next support...... ~ $2.11 JMHO
(81)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 22, 2022 12:15pm
SPRO .....vols are decreasing and.....
Price action is "sideways" ....or in other words "Range Bound" Me no position Still on watch
(81)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 22, 2022 10:54am
SPRO ...... I managed to get another small position
just before this big rally into the gap I have a habit of " taking profits way too early" Sold it over $2.60 Watching & waiting now......me no position Cheers !
(81)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 22, 2022 10:48am
SPRO ...... Now into "The Gap"
Next resistance is $4.65 ..... I stand corrected
(81)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 22, 2022 10:43am
SPRO ...... It's official LoL
Broke the $2.34 Here is hoping for more fireworks..... $4 holla ?
(81)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 22, 2022 10:40am
SPRO ..... Yeeeha
Cheers folks
(81)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 22, 2022 10:38am
SPRO ...... I will be buying the dip ; )
Watching and waiting ; )
(81)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 22, 2022 10:35am
SPRO ...... Sold to America
I always like to leave some for the next guy Cheers .....hoping it breaks the $2.33 for ya !
(81)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 22, 2022 10:33am
SPRO .....That';s more like it
Nice wait for it
(81)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 22, 2022 10:21am
SPRO .....it broke the high..... N>H>O>D
Now rocket u beotch !!!!! Vols are increasing ; )
(81)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 22, 2022 10:20am
SPRO .....Looking Real good......
wait for it
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{currentVideo.storiesTitle}}:
{{story.companySymbol}}
{{story.companySymbol}}
{{story.headline}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
A Digital Advertising Company Announces Updated Commercial Agreements with Large National Retailers
Bob Moriarty: Lithium South (TSXV:LIS) is a Real Deal Lithium Company
Company Announces Name Change as They Turn Full Focus to Gold
SolarBank Completes Sale of 21MW Community Solar Sites to Honeywell International for $41mn